


FTSE Global Health Tech Index

Data as at: 30 June 2025

The FTSE Global Health Tech Index is a liquidity-weighted thematic index based on the FTSE Global All Cap Index which includes large, mid, and small-cap securities globally. The index employs natural language processing techniques in selecting constituents associated with the underlying theme. The index is designed to represent the performance of companies that provide innovative medical equipment or devices, as well as healthcare software or technology solutions. This theme also includes companies engaged in digital health platforms, such as online health consultation.

5-Year Performance - Total Return



Performance and Volatility - Total Return

Index (USD)	Return %						Return pa %*		Volatility %**		
	3M	6M	YTD	12M	3YR	5YR	3YR	5YR	1YR	3YR	5YR
FTSE Global Health Tech	5.5	6.6	6.6	9.5	20.6	27.0	6.4	4.9	14.5	14.9	16.2
FTSE Global Health Tech Net Tax	5.5	6.5	6.5	9.3	19.8	25.7	6.2	4.7	14.5	14.9	16.2
FTSE Global Equity Index Series wi All Cap	11.7	10.2	10.2	16.5	61.6	91.6	17.3	13.9	14.6	14.0	15.3

* Compound annual returns measured over 3 and 5 years respectively

** Volatility – 1YR based on 12 months daily data. 3YR based on weekly data (Wednesday to Wednesday). 5YR based on monthly data

Year-on-Year Performance - Total Return

Index % (USD)	2020	2021	2022	2023	2024
FTSE Global Health Tech	30.7	13.0	-23.1	8.3	4.2
FTSE Global Health Tech Net Tax	30.5	12.8	-23.3	8.1	4.0
FTSE Global Equity Index Series wi All Cap	16.8	18.5	-17.9	22.2	16.8

Return/Risk Ratio and Drawdown - Total Return

Index (USD)	Return/Risk Ratio				Drawdown (%)			
	1YR	3YR	5YR	10YR	1YR	3YR	5YR	10YR
FTSE Global Health Tech	0.6	0.3	0.3	-	-17.0	-17.0	-33.1	-
FTSE Global Health Tech Net Tax	0.6	0.3	0.3	-	-17.1	-17.1	-33.2	-
FTSE Global Equity Index Series wi All Cap	1.1	1.2	0.9	0.7	-15.9	-16.2	-26.1	-34.3

Return/Risk Ratio – based on compound annual returns and volatility in Performance and Volatility table

Drawdown - based on daily data

FEATURES

Objective

The indexes are designed for the creation of index tracking funds, derivatives and as a performance benchmark.

Investability

The index follows a liquidity weighting scheme with a weight cap mechanism to achieve an overall more diversified, better liquidity investable opportunity set.

Capping

Constituents are capped quarterly in March, June, September and December so that no more than 5% of the indexes weight may be allocated to a single constituent.

Liquidity

Stocks in the underlying universe are liquidity screened to ensure tradability.

Transparency

The index uses a transparent, rules-based construction process. Index methodologies are freely available on the FTSE Russell website.

Availability

The indexes are calculated based on price, total return, and net total return methodologies, and available end-of-day.

Industry Classification Benchmark (ICB)

Index constituents are categorized in accordance with the Industry Classification Benchmark (ICB), the global standard for industry sector analysis.

Top 10 Constituents

Constituent	Country/Market	ICB Sector	Net MCap (USDm)	Wgt %
Wuxi Apttec (A) (SC SH)	China	Pharmaceuticals and Biotechnology	4,429,867	5.17
SK Hynix	Korea	Technology Hardware and Equipment	4,312,519	5.03
Abbott Laboratories	USA	Medical Equipment and Services	4,068,221	4.75
Intuitive Surgical	USA	Medical Equipment and Services	3,646,597	4.26
Boston Scientific Corp	USA	Medical Equipment and Services	3,458,055	4.04
Thermo Fisher Scientific	USA	Medical Equipment and Services	3,079,479	3.59
Zoetis	USA	Pharmaceuticals and Biotechnology	2,878,045	3.36
Medtronic plc	USA	Medical Equipment and Services	2,846,776	3.32
Danaher Corp	USA	Medical Equipment and Services	2,760,997	3.22
Stryker	USA	Medical Equipment and Services	2,576,793	3.01
Totals			34,057,349	39.75

ICB Industry Breakdown

ICB Code	ICB Industry	No. of Cons	Net MCap (USDm)	Wgt %
10	Technology	13	11,427,081	13.34
20	Health Care	131	64,612,010	75.42
30	Financials	1	108,340	0.13
40	Consumer Discretionary	1	109,632	0.13
45	Consumer Staples	5	2,949,408	3.44
50	Industrials	11	5,678,560	6.63
55	Basic Materials	6	784,075	0.92
Totals		168	85,669,107	100.00

Country/Market Breakdown

Country/Market	No. of Cons	Net MCap (USDm)	Wgt %
Australia	3	297,336	0.35
China	54	13,053,478	15.24
Denmark	2	112,798	0.13
France	1	77,839	0.09
Germany	6	2,459,343	2.87
Italy	1	93,421	0.11
Japan	14	3,514,289	4.10
Korea	5	5,710,331	6.67
Netherlands	1	240,307	0.28
Saudi Arabia	1	63,388	0.07
Spain	1	197,515	0.23
Sweden	2	254,259	0.30
Switzerland	4	611,334	0.71
Taiwan	1	1,773,144	2.07
UK	3	503,898	0.59
USA	69	56,706,427	66.19
Totals	168	85,669,107	100.00

Index Characteristics

Attributes	FTSE Global Health Tech
Number of constituents	168
Dividend Yield %	0.94
Constituent (Wgt %)	
Average	0.60
Largest	5.17
Median	0.21
Top 10 Holdings (Wgt %)	39.75

INFORMATION

Index Universe

FTSE Global All Cap Index

Index Launch

4 February 2022

Base Date

18 June 2021

Base Value

1000

Index Calculation

Available end-of-day

End-of-Day Distribution

Via FTP and email

Currency

USD, GBP, EUR, JPY, AUD, CNY, HKD, CAD

Review Dates

Annually in June

History

Available from June 2016

© 2025 London Stock Exchange Group plc and its applicable group undertakings ("LSEG"). LSEG includes (1) FTSE International Limited ("FTSE"), (2) Frank Russell Company ("Russell"), (3) FTSE Global Debt Capital Markets Inc. "FTSE Canada", (4) FTSE Fixed Income LLC ("FTSE FI"), (5) FTSE (Beijing) Consulting Limited ("WOFE"). All rights reserved.

FTSE Russell® is a trading name of FTSE, Russell, FTSE Canada, FTSE FI, WOFE, and other LSEG entities providing LSEG Benchmark and Index services. "FTSE®", "Russell®", "FTSE Russell®", "FTSE4Good®", "ICB®", "Refinitiv" , "Beyond Ratings®", "WMR™" , "FR™" and all other trademarks and service marks used herein (whether registered or unregistered) are trademarks and/or service marks owned or licensed by the applicable member of LSEG or their respective licensors.

FTSE International Limited is authorised and regulated by the Financial Conduct Authority as a benchmark administrator.

All information is provided for information purposes only. All information and data contained in this publication is obtained by LSEG, from sources believed by it to be accurate and reliable. Because of the possibility of human and mechanical inaccuracy as well as other factors, however, such information and data is provided "as is" without warranty of any kind. No member of LSEG nor their respective directors, officers, employees, partners or licensors make any claim, prediction, warranty or representation whatsoever, expressly or impliedly, either as to the accuracy, timeliness, completeness, merchantability of any information or LSEG Products, or of results to be obtained from the use of LSEG products, including but not limited to indices, rates, data and analytics, or the fitness or suitability of the LSEG products for any particular purpose to which they might be put. The user of the information assumes the entire risk of any use it may make or permit to be made of the information.

No responsibility or liability can be accepted by any member of LSEG nor their respective directors, officers, employees, partners or licensors for (a) any loss or damage in whole or in part caused by, resulting from, or relating to any inaccuracy (negligent or otherwise) or other circumstance involved in procuring, collecting, compiling, interpreting, analysing, editing, transcribing, transmitting, communicating or delivering any such information or data or from use of this document or links to this document or (b) any direct, indirect, special, consequential or incidental damages whatsoever, even if any member of LSEG is advised in advance of the possibility of such damages, resulting from the use of, or inability to use, such information.

No member of LSEG nor their respective directors, officers, employees, partners or licensors provide investment advice and nothing in this document should be taken as constituting financial or investment advice. No member of LSEG nor their respective directors, officers, employees, partners or licensors make any representation regarding the advisability of investing in any asset or whether such investment creates any legal or compliance risks for the investor. A decision to invest in any such asset should not be made in reliance on any information herein. Indices and rates cannot be invested in directly. Inclusion of an asset in an index or rate is not a recommendation to buy, sell or hold that asset nor confirmation that any particular investor may lawfully buy, sell or hold the asset or an index or rate containing the asset. The general information contained in this publication should not be acted upon without obtaining specific legal, tax, and investment advice from a licensed professional.

Past performance is no guarantee of future results. Charts and graphs are provided for illustrative purposes only. Index and/or rate returns shown may not represent the results of the actual trading of investable assets. Certain returns shown may reflect back-tested performance. All performance presented prior to the index or rate inception date is back-tested performance. Back-tested performance is not actual performance, but is hypothetical. The back-test calculations are based on the same methodology that was in effect when the index or rate was officially launched. However, back-tested data may reflect the application of the index or rate methodology with the benefit of hindsight, and the historic calculations of an index or rate may change from month to month based on revisions to the underlying economic data used in the calculation of the index or rate.

No part of this information may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, without prior written permission of the applicable member of LSEG. Use and distribution of LSEG data requires a licence from LSEG and/or its licensors.

Data definitions available from
info@ftserussell.com

To learn more, visit lseg.com/ftse-russell;
email info@ftserussell.com; or
call your regional Client Services Team office:

EMEA

+44 (0) 20 7866 1810

North America

+1 877 503 6437

Asia-Pacific

Hong Kong +852 2164 3333
Tokyo +81 3 6441 1430
Sydney +61 (0) 2 7228 5659